The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
IN MEMORIAM: MENSO BULT +
Menso Bult, European Manager for Plasma Protein Therapeutic Association’s (PPTA) global access activities, passed away after a long illness on March 3, 2014.
Rare Disease Day Congressional Tele-Town Hall +
On February 28, 2014, the Plasma Protein Therapeutics Association (PPTA) hosted a Rare Disease Day Congressional Tele-Town Hall featuring remarks by Congressman Leonard Lance (NJ-7), Co-Chair of the Congressional Rare Disease Caucus, and Dr. Stephen Groft, Pharm. D., Former Director of the Office of Rare Disease Research, National Institutes of Health (NIH).Read More
PPTA Recognizes International Rare Disease Day 2014 +
The Plasma Protein Therapeutics Association (PPTA) joins over 300 organizations in 56 countries in recognizing the 7th annual International Rare Disease Day on February 28.Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly.
Read the current issue.